Navigation Links
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Date:11/20/2008

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at http://www.epeiusbiotech.com .

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
4. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. New Insight Into the Controls on a Go-To Enzyme
7. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
8. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
9. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Seeger Weiss LLP is reporting that on ... warning letter to C.R. Bard, the manufacturer of Inferior ... to correct violations the agency found at two of Bard,s ... the FDA cited them during Inspectional Observations that occurred on ... Tempe, AZ , location and on October 6, ...
(Date:7/31/2015)... , July 31, 2015 The Physician-Patient ... release on July 28, 2015, "Surviving Your Hospital ... Fundraising for Patient Safety." A sentence ... should read: "PPAHS is a member ... on Opioids. For more information on the National Coalition ...
(Date:7/31/2015)... -- Quietly, sedately, Morocco,s pharmaceutical sector is ... industry is strong, with a well-developed base of local ... One place where the quality of Moroccan ... has quietly become the second largest African exporter of ... Indeed, Moroccan pharma companies have been making inroads as ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... , LYNBROOK, N.Y., Nov. 24 BioSpecifics Technologies Corp. (Nasdaq: ... collagenase-based products, today announced that BioSpecifics, President, Tom Wegman, will ... Conference on Tuesday, December 1, 2009, at 3:30pm ET at ... A live webcast of the presentation can be accessed under ...
... , , CHICAGO, Nov. 23 Two ... introducing a new era in women,s breast imaging, coupling the ... with the ability to have the full range of digital ... leaves the office. Drs. Ahmed Farag and Joan Werber ...
Cached Medicine Technology:Noted Diagnostic Radiologists Joan Werber, D.O., Ahmed Farag, M.D., C.M., Join Forces to Create Diagnostic Imaging Specialists of Chicago 2
(Date:7/31/2015)... ... ... The 2nd annual Ride to Fight On will start and end near the ... to Fight On is a cycling fundraiser that benefits the West Cancer Center, a ... University of Tennessee Health Science Center. A health and wellness festival featuring food, music, ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to enjoy ... comes time to cook the next meal, making July the most appropriate to be ... grilling tips and recipes. , Make the next cookout different than the ones in ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, ... Inc. has re-branded their social media profiles to better connect with the public. ... to communicate, find information, share insights and opinions. The Rally Insurance Group, Inc.’s ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... M3 USA ... excited to launch three new Board Exam Courses. , The additions of Gastroenterology, ... Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... Angeles, CA (PRWEB) , ... July 31, 2015 , ... According to the article ... third floor of the Pasadena courthouse was contained and extinguished by the city’s fire department ... was in the building at the time of the fire, and it was a fire ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... method to monitor the production and clearance rates of ... brain disorders. // ,Amyloid Beta Peptide ... humans can now be possibly diagnosed with the new ... School of Medicine in St. Louis. ,Media ...
... high-blood pressure are at a higher risk for ... ,In a study released today, "Impaired stress ... in African American youth at risk of hypertension," ... identify youth at risk for deteriorating endothelial function. ...
... Health Minister P. K. Sreemathy has announced in Thiruvananthapuram ... sanctioning 50 MBBS seats //each for medical collages in ... on Thursday, while replying to questions in the Assembly ... with the medical council. She further alleged that though ...
... North America (SANA) has welcomed the new recommendations issued ... eating foods high in fiber and using vegetable-based substitutes, ... trans fat, and cholesterol in the diet are decreased. ... by the AHA, providing fiber, high-quality protein, vitamins and ...
... Recently there has been an increase in the age ... as erectile dysfunction or ED in the scenario. Patients ... the problem. While oral medications for ED, known as ... all men respond equally. Through a series of studies, ...
... appears to be three variations of a human gene ... their susceptibility towards tuberculosis// . Researchers hope that these ... patients infected with the Mycobacterium tuberculosis pathogen develop the ... findings was published in the online edition of the ...
Cached Medicine News:Health News:Abnormal Abeta - Protein Level in Human Brain Trigger Alzheimer's Risk 2Health News:Abnormal Abeta - Protein Level in Human Brain Trigger Alzheimer's Risk 3Health News:Mental Stress Linked To Higher Risk Of Heart Disease 2Health News:Soyfoods Are Ideal For The Heart 2Health News:Non Surgical Medication Drugs Prove To Be Effective In Treating ED 2Health News:Susceptibility Of TB In Humans Might Be Due To Three Human Gene Variants 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: